Masaki Kashiwara wins Abel Prize for mathematicians
Kashiwara, 78, a specially appointed professor at Kyoto University's Research Institute for Mathematical Sciences, won the award for "his fundamental contributions to algebraic analysis and representation theory, in particular the development of the theory of D-modules and the discovery of crystal bases," the academy said.
Masaki Kashiwara, a specially appointed professor at Kyoto University's Research Institute for Mathematical Sciences, won this year's Abel Prize. |
Jiji
"He has proven astonishing theorems with methods no one had imagined. He has been a true mathematical visionary," it said.
The Abel Prize, often regarded as the Nobel Prize in mathematics, comes with a monetary award of 7.5 million Norwegian kroner ($710,000, ¥107 million). The prize ceremony is scheduled to take place in Oslo on May 20.
Kashiwara contributed to the development of modern mathematics by building from the foundation the theory of D-modules, which is the central concept of algebraic analysis.
In the 1980s, he greatly contributed to the development of various fields of modern mathematics, including solving the Riemann-Hilbert problem, which had been a pending issue among mathematicians since the early 20th century.
He has received various awards, including the Japan Academy Prize in 1988 and the Chern Medal of the International Mathematical Union in 2018.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Nikkei Asia
8 hours ago
- Nikkei Asia
Sumitomo Pharma files for approval of stem cell Parkinson's treatment
Induced pluripotent stem cell technology was developed in Japan in 2007, but progress on developing treatments for diseases has been slow. (Photo obtained by Nikkei) NANAKO TAKEUCHI, YUKI MISUMI and AKANE ASAMI OSAKA/TOKYO -- Japanese drugmaker Sumitomo Pharma has applied for approval in Japan of a stem cell-based Parkinson's disease treatment, it announced on Tuesday, looking to ease the motor symptoms of sufferers and help push the country's stem cell treatment implementation forward.
Japan Times
9 hours ago
- Japan Times
Drugmaker in Japan seeks approval for stem cell treatment for Parkinson's
Sumitomo Pharma said Tuesday it is seeking approval for a Parkinson's disease treatment that transplants stem cells into a patient's brain, following a successful clinical trial. The drugmaker applied to Japanese regulators for manufacturing and marketing authorization aimed at treating patients with advanced Parkinson's disease, it said in a statement. A trial led by Kyoto University researchers indicated that the company's treatment using induced Pluripotent Stem (iPS) cells — which have the potential to develop into any cell in the body — was safe and successful in improving symptoms. The study involved seven Parkinson's patients between 50 and 69 years old, with each receiving a total of either 5 million or 10 million cells implanted on both sides of the brain. The iPS cells from healthy donors were developed into the precursors of dopamine-producing brain cells, which are no longer present in people with Parkinson's disease. The patients were monitored for two years, and no major adverse effects were found, the study said. Four patients showed improvements in symptoms, it said. The trial results were published in Nature in April. Sumitomo Pharma is also carrying out a clinical trial in the United States. Parkinson's disease is a chronic, degenerative neurological disorder that affects the body's motor system, often causing shaking and other difficulties in movement. Worldwide, about 10 million people have the illness, according to the Parkinson's Disease Foundation. Currently available therapies "improve symptoms without slowing or halting the disease progression," the foundation said. iPS cells are created by stimulating mature, already specialized, cells back into a juvenile state — basically cloning without the need for an embryo. The cells can be transformed into a range of different types of cells, and their use is a key sector of medical research.
Japan Times
14 hours ago
- Japan Times
Kyoto University team develops pain reliever comparable to morphine
A Kyoto University research team has developed a pain-reliever that is comparable to morphine but does not have serious side effects. Morphine, often administered to cancer patients, has serious adverse effects such as breathing issues and addiction. According to the team, the newly developed drug, Adriana, is a groundbreaking painkiller, which works on a completely different mechanism to morphine and other existing synthetic opioids. The drug has the potential to revolutionize pain control in the medical field, the team said. The team also expects that the drug will help resolve the so-called opioid epidemic, in which a large number of deaths occur mainly due to overdoses of opioids. Its findings were published in the online edition of the U.S. journal Proceedings of the National Academy of Sciences. When a person encounters a life-threatening situation, norepinephrine, an organic chemical secreted from the brain, suppresses pain. For its study, the team focused on the human body regulating oversecretion of norepinephrine. By introducing a new research technology, the team succeeded in developing a drug blocking such a control function for the first time in the world. In a clinical trial conducted at the Kyoto University Hospital between January 2023 and December 2024, the team confirmed the new drug's efficiency to a certain extent for patients including 20 who underwent lung cancer surgery. The team plans to conduct a clinical trial in the United States for 400 postsurgery patients in 2026, aiming to put Adriana into practical use in 2028. "We hope that the new drug will help cancer patients who previously had no choice but to use opioids live their lives without pain as well as a need to worry about addiction or serious side effects," Masatoshi Hagiwara, a professor at the university, said.
